Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2359-2363

  Zhang, Yizhuo ^a   Zhao, Dandan ^b   Zhao, Haifeng ^a   Wu, Xiaoxiong ^b   Zhao, Weipeng ^a   Wang, Yafei ^a   Xia, Bing ^a   Da, Wanming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Methylation; Myelodysplastic syndrome; SHP 1; STAT3

Indexed keywords

JANUS KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CHILD; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHORYLATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RISK; SEQUENCE ANALYSIS, DNA; STAT3 TRANSCRIPTION FACTOR;

EID: 84868004547     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0163-6     Document Type: Article

References (16)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-28.
3. Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 2008;32:1541-5.
4. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol. 2006;135:317-23.
5. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol. 2006;76:23-32.
6. Grovdal M, Khan R, Aggerholm A, et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res. 2007;13:7107-12.
7. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003;306:1-12.
8. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-88.
9. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109:1139-42.
10. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, et al. Gene silencing of the tyrosine phosphastase SHP1 by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390-4.
11. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood. 2004;103:4630-5.
12. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168:466-74.
13. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143-64.
14. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Natl Rev Mol Cell Biol. 2002;3:651-62.
15. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer. 2003;89:344-9.
16. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 2000;95:3765-70.